BenzingaAugust 14, 2026 at 6:15 AM NY21 days ago
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Yahoo4 hours ago
Which dow jones stocks are moving on Friday?
ChartMill4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill4 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo5 hours ago
Sector Update: Financial
Yahoo6 hours ago